The second-largest shareholder in Ariad Pharmaceuticals made it clear in a filing today it wants to see CEO Harvey Berger gone, and according to one investor, several other of the company's largest shareholders agree. In a filing with the Securities and Exchange Commission this morning, Sarissa Capital, which owns a 7 percent stake in the Cambridge drugmaker said that "it is in the best interests of the issuer and its shareholders that the board undertake measures to effect and facilitate the imminent retirement of Harvey Berger as CEO."